Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1T90L | ISIN: SE0005162880 | Ticker-Symbol: DMN
München
24.04.25
08:03 Uhr
0,707 Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
DIAMYD MEDICAL AB Chart 1 Jahr
5-Tage-Chart
DIAMYD MEDICAL AB 5-Tage-Chart

Aktuelle News zur DIAMYD MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiDIAMYD MEDICAL AB: Shareholders in Diamyd Medical, including the Chairman of the Board, have provided additional subscription commitments in the ongoing rights issue2
MoDiamyd Medical AB: Diamyd Medical highlights opportunity in Type 1 Diabetes prevention, adult-onset market, and upcoming Phase 3 readout230STOCKHOLM, April 21, 2025 /PRNewswire/ -- In a recent investor interview, Diamyd Medical Board Member Professor Mark Atkinson and CEO Ulf Hannelius shared key insights into the Company's...
► Artikel lesen
17.04.DIAMYD MEDICAL AB: The prevention trial DiaPrecise with Diamyd® clears first safety milestone1
15.04.DIAMYD MEDICAL AB: Australia grants Diamyd Medical patent for novel antigen combination in autoimmune diabetes treatment4
15.04.Diamyd Medical AB (publ): Australia grants Diamyd Medical patent for novel antigen combination in autoimmune diabetes treatment101The Australian Patent Office has granted a patent protecting a novel immunotherapeutic composition developed by Diamyd Medical for use in the treatment and prevention of autoimmune diabetes. The patent...
► Artikel lesen
14.04.DIAMYD MEDICAL AB: Diamyd Medical publishes prospectus with regards to the rights issue1
09.04.Diamyd Medical AB (publ): Quarterly Report 2 24/2586Diamyd Medical today announces in its second quarterly report for fiscal year 2024/2025 continued progress toward a transformative regulatory milestone, with early Phase 3 results from the DIAGNODE-3...
► Artikel lesen
09.04.XFRA CAPITAL ADJUSTMENT INFORMATION - 09.04.2025114Das Instrument N7S CA87043J2039 SWEET POISON SPIRITS INC. EQUITY wird cum Kapitalmassnahme gehandelt am 09.04.2025 und ex Kapitalmassnahme am 10.04.2025 The instrument N7S CA87043J2039 SWEET POISON...
► Artikel lesen
DIAMYD MEDICAL Aktie jetzt für 0€ handeln
21.03.DIAMYD MEDICAL AB: Diamyd Medical announces additional subscription commitments for upcoming rights issue1
17.03.DIAMYD MEDICAL AB: Diamyd Medical highlights clinical benefits of C-peptide preservation at ATTD 20251
13.03.Diamyd Medical AB (publ): Diamyd Medical advances AI-powered screening for Type 1 Diabetes within the ASSET Project123Diamyd Medical, in collaboration with Mainly AI and ASSET partners, highlights meaningful progress in AI-driven screening and risk prediction for Type 1 Diabetes at the Advanced Technologies & Treatments...
► Artikel lesen
10.03.DIAMYD MEDICAL AB: Diamyd Medical announces additional subscription commitments for upcoming rights issue3
28.02.DIAMYD MEDICAL AB: The Board of Directors in Diamyd Medical has resolved on a rights issue of approximately SEK 208 million3
20.02.DIAMYD MEDICAL AB: Diamyd Medical precision medicine patent for prevention and treatment of autoimmune diabetes to be granted in Mexico2
18.02.Diamyd Medical AB (publ): Diamyd Medical's CFO to leave in 2025102Diamyd Medical announced today that Anna Styrud, CFO, has decided to step down from her position. During her 15 years as CFO, she has successfully navigated the financial markets and played a key role...
► Artikel lesen
12.02.Diamyd Medical AB: Diamyd Medical announces expanded financial support from Breakthrough T1D384STOCKHOLM, Feb. 12, 2025 /PRNewswire/ -- Diamyd Medical will receive USD 1.75 million in expanded collaboration support from Breakthrough T1D (formerly JDRF), the world's leading Type 1 Diabetes...
► Artikel lesen
29.01.Diamyd Medical AB (publ): Quarterly Report 1 24/2575September 2024 - November 2024, Diamyd Medical AB (publ), Fiscal year 2024/2025 Precision Medicine for Autoimmune Diabetes Aiming for Accelerated Market Approval Diamyd Medical's B-share is traded...
► Artikel lesen
21.01.DIAMYD MEDICAL AB: South Korea to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in autoimmune diabetes2
13.01.Diamyd Medical AB: Diamyd Medical updates U.S. market potential for Diamyd386STOCKHOLM, Jan. 13, 2025 /PRNewswire/ -- Diamyd Medical has released an updated analysis of the commercial potential for its lead product candidate, the precision immunotherapy Diamyd® (rhGAD65/alum)...
► Artikel lesen
10.01.Diamyd Medical AB: Diamyd Medical confirms key advances toward Accelerated Approval for Diamyd following FDA Type C Meeting1.405STOCKHOLM, Jan. 10, 2025 /PRNewswire/ -- Diamyd Medical provides an update following the receipt of final meeting minutes from a positive Type C meeting with the U.S. Food and Drug Administration...
► Artikel lesen
Seite:  Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1